News
The Indiana Department of Health is hosting the 39th Annual Indiana Health Fair this weekend, offering Hoosiers access to free health services.
GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...
Researcher say the increase in carbapenemase-producing Enterobacterales infection and colonization is being driven by ...
Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results